stephen doberstein  nektar therapeutics  zoominfocom microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext7 legal privacy  cookies   microsoft stephen k doberstein nektar therapeutics chief scientific officer  svp  redbooks brands marketers agencies search less sell more    sign in get a free trial    contact us   stephen k doberstein chief scientific officer  svp nektar therapeutics email realtime sales trigger feed  generated by redbooks machine learning and natural language processing technology tracking  news sources to aggregate all new executives jobrole changes and news on decision makers brands and agencies in the mediamarketing industry this sales feed is for stephen k doberstein at nektar therapeutics stephen k doberstein works as chief scientific officer  svp  nektar therapeutics is a leader in pharmaceuticals  health care products  redbooks tracks personnel changes for advertisers spending over  million annually for more leads or mediamarketing prospecting automation start a free trial now recent related news  zacks brokerages expect nektar therapeutics nktr will announce quarterly sales of  million posted by lucas kauffman on jul th   no comments equities research analysts expect nektar therapeutics nasdaqnktr to report  million in sales for the current quarter according to zacks  five analysts have issued estimates for nektar therapeutics’ earnings the lowest sales estimate is  million and the highest is  million nektar therapeutics posted sales of  million during the same quarter last year which would indicate a positive year over year growth rate of   people in this article robert b chess  stephen k doberstein  somewhat negative press coverage somewhat likely to impact nektar therapeutics nktr stock price press coverage about nektar therapeutics nasdaqnktr has been trending somewhat negative this week according to accern sentiment the research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources accern ranks coverage of companies on a scale of negative one to positive one with scores closest to one being the most favorable nektar therapeutics earned a media sentiment score of 9 on accern’s scale  people in this article stephen k doberstein learn more about stephen k doberstein and  key contacts   create targeted lead lists   gain insider knowledge with advanced machine  learning   realtime verified contact info enter work email please enter email address please enter valid email address learn more about stephen k doberstein and  key contacts first name  please enter first name last name  please enter last name company name  please enter company name email  phone  please enter phone number please enter  digits number what industry are you in    please select one the categories below please enter value for the industry  media sales  production  adtechmartech  sponsorship sales   agency new business   other what is your role    please select one the categories below please enter value for the role   csuite   vpmanager   sales rep   other thank you for registering for a free redbookscom trial we are processing your request and will be in touch shortly to get you started for immediate assistance please call us at   or email us at inforedbookscom home learn more free trial features ad think events thought leadership events top advertiser directory top agency directory add your agency update your agency agency showcase advertising associations creative spotlight services and suppliers about us blog contact us jobs terms  conditions privacy policy customer support   connect with us copyright   red books llc all rights reserved nektar therapeutics names stephen k doberstein phd senior vice president and chief scientific officer skip to main content advertisement home topicsbig pharma contract manufacturing drug development enterprise technology facility global operations recalls regulatory supply chain watchinterphex live search eventsinterphex socialfacebook twitter youtube guidescompanies products learn digital login register subscribe channelsmnet chem fm id impo mbt advertisement advertisement operations nektar therapeutics names stephen k doberstein phd senior vice president and chief scientific officer thu   am comments by nektar therapeutics has announced the appointment of stephen k doberstein phd to the position of senior vice president and chief scientific officer dr doberstein will report to nektars president and chief executive officer howard w robin dr doberstein brings over 7 years of experience in biotechnology research and development to nektar in this newlycreated role he will lead all aspects of discovery research at nektar we are delighted to have steve join the nektar executive team as we execute on our research strategy to develop innovative therapeutics with our proven polymer conjugate technology platform said howard w robin president and chief executive officer of nektar therapeutics steve is a highly talented executive with an impressive track record his experience and leadership will be instrumental as we continue to build our pipeline of proprietary drug candidates prior to joining nektar dr doberstein  was vice president of research at xoma where he was responsible for directing the discovery and development of their drug candidates including antibody discovery and support of clinical development through nonclinical safety translational medicine and pharmacokineticspharmacodynamics prior to that dr doberstein served as vice president research at five prime therapeutics inc a protein and antibody discovery and development company where he built and led a high performance discovery research and process development group while at five prime he established programs resulting in multiple strategic alliances with pharmaceutical partners built a strong proprietary pipeline and moved multiple product candidates from concept to preind stages in diabetes oncology rheumatoid arthritis and osteoarthritis prior to that dr doberstein was vice president research at xencor an antibody and protein engineering and development company at xencor he was instrumental in advancing its protein platform technologies and preclinical product candidates before that he also held a number of senior positions at exelixis dr doberstein received his phd in biochemistry cell and molecular biology from the johns hopkins university school of medicine and completed his postdoctoral work at uc berkeley earlier in his career dr doberstein held a variety of engineering roles at dupont after receiving his bsche degree in chemical engineering from the university of delaware i am excited to join nektar the clear industry leader in pegylation chemistry and advanced polymer conjugate technologies said dr doberstein nektars innovative drug discovery and development platform is among the most promising in the biopharmaceutical industry i look forward to working with nektars worldclass research scientists to apply this platform to the discovery of new drug candidates and to advance nektars discoveries rapidly into the clinic advertisement advertisement view the discussion thread connect with pharmaceutical processing facebook twitter youtube resources about us advertising info contact us contributor guidelines directory faqs privacy policy product announcement form rss subscriptions terms  conditions topics big pharma contract manufacturing drug development enterprise technology facility global operations recalls regulatory supply chain  copyright  advantage business media advertisement nektar therapeutics names stephen k doberstein phd senior vice president and chief scientific officer  jan   home  media  contact about nektar overview leadership management board of directors partnering our partners partner case studies partnering events locations our locations nektar therapeutics corporate headquarters nektar alabama nektar therapeutics india private limited contact rd pipeline products in development product pipeline oncology  etirinotecan pegol nktr cnspain  movantik naloxegol  nktr  nktr7 antiinfectives  nktr bay clinical trials information approved products scientific  medical event calendar platform technologies our technology approved products investor relations overview financial calendar  presentations news  email alerts email alerts stock information historic stock lookup analyst coverage financial information sec filings annual reports quarterly results corporate governance investor contacts careers overview life at nektar search jobs benefits at nektar overview benefits at san francisco california benefits at huntsville alabama benefits at hyderabad india information for recruiters print this page  tell a friend  rss print this page media room news releases company overview broadcast video image gallery media contacts news releases nektar therapeutics names stephen k doberstein phd senior vice president and chief scientific officer nektar therapeutics today announced the appointment of stephen k doberstein phd to the position of senior vice president and chief scientific officer dr doberstein will report to nektars president and chief executive officer howard w robin dr doberstein brings over 7 years of experience in biotechnology research and development to nektar in this newlycreated role he will lead all aspects of discovery research at nektar we are delighted to have steve join the nektar executive team as we execute on our research strategy to develop innovative therapeutics with our proven polymer conjugate technology platform said howard w robin president and chief executive officer of nektar therapeutics steve is a highly talented executive with an impressive track record his experience and leadership will be instrumental as we continue to build our pipeline of proprietary drug candidates prior to joining nektar dr doberstein  was vice president of research at xoma where he was responsible for directing the discovery and development of their drug candidates including antibody discovery and support of clinical development through nonclinical safety translational medicine and pharmacokineticspharmacodynamics prior to that dr doberstein served as vice president research at five prime therapeutics inc a protein and antibody discovery and development company where he built and led a high performance discovery research and process development group while at five prime he established programs resulting in multiple strategic alliances with pharmaceutical partners built a strong proprietary pipeline and moved multiple product candidates from concept to preind stages in diabetes oncology rheumatoid arthritis and osteoarthritis prior to that dr doberstein was vice president research at xencor an antibody and protein engineering and development company at xencor he was instrumental in advancing its protein platform technologies and preclinical product candidates before that he also held a number of senior positions at exelixis dr doberstein received his phd in biochemistry cell and molecular biology from the johns hopkins university school of medicine and completed his postdoctoral work at uc berkeley earlier in his career dr doberstein held a variety of engineering roles at dupont after receiving his bsche degree in chemical engineering from the university of delaware i am excited to join nektar the clear industry leader in pegylation chemistry and advanced polymer conjugate technologies said dr doberstein nektars innovative drug discovery and development platform is among the most promising in the biopharmaceutical industry i look forward to working with nektars worldclass research scientists to apply this platform to the discovery of new drug candidates and to advance nektars discoveries rapidly into the clinic about nektar nektar therapeutics is a biopharmaceutical company developing novel therapeutics based on its pegylation and advanced polymer conjugation technology platforms nektars technology and drug development expertise have enabled nine approved products in the us or europe for leading biopharmaceutical company partners including ucbs cimzia® for crohns disease and rheumatoid arthritis roches pegasys® for hepatitis c and amgens neulasta® for neutropenia nektar has created a robust pipeline of potentially highvalue therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules nektar is currently conducting clinical and preclinical programs in oncology pain and other therapeutic areas nektar recently entered into an exclusive worldwide license agreement with astrazeneca for its oral nktr program to treat opioidinduced constipation and its nktr9 program for the treatment of pain without constipation side effects nktr pegylated irinotecan is currently being evaluated in phase  clinical studies for the treatment of ovarian breast and colorectal cancers nktr pegylated docetaxel is currently in a phase  clinical study in cancer patients with refractory solid tumors nektar is headquartered in san carlos california with additional rd operations in huntsville alabama and hyderabad india further information about the company and its drug development programs and capabilities may be found online at httpwwwnektarcom this press release contains forwardlooking statements that reflect managements current views regarding the value and potential of nektars technology platform nektars pipeline of product candidates in development and nektars collaborations with third parties these forwardlooking statements involve risks and uncertainties including but not limited to i nektars proprietary product candidates and those of its partners are in the early to midstage phases of clinical development and the risk of failure is high and can occur at any stage prior to regulatory approval ii nektar or its partners may not be able to successfully obtain regulatory approval for product candidates in development iii nektars commercialization partners may not be successful in their sales and marketing efforts even if current product candidates successfully receive future regulatory approval in one or more markets iv nektars patent applications for its technology platforms and proprietary or partner product candidates may not issue patents that have issued may not be enforceable and or intellectual property licenses from third parties may be required in the future and v other important risks and uncertainties set forth in nektars most recent quarterly report on form q filed on november  9 and its annual report on form k filed with the securities and exchange commission on march  9 actual results could differ materially from the forwardlooking statements contained in this press release nektar undertakes no obligation to update forwardlooking statements whether as a result of new information future events or otherwise for more information on nektar therapeutics please visit wwwnektarcom jennifer ruddock  first call analyst fcmn contact jruddocknektarcom source nektar therapeutics contact jennifer ruddock of nektar therapeutics  web site httpwwwnektarcom     site map privacy terms of use compliance policy trademarks site users guide copyright nektar   stephen k doberstein senior vice president and chief scientific officer nektar therapeutics timesjavascript is disabled market profiles login sign up login sign up   edit person stephen k doberstein senior vice president and chief scientific officer at nektar therapeutics location san francisco bay area ca add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop stephen k doberstein senior vice president and chief scientific officer at nektar therapeutics location san francisco bay area ca add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop steve doberstein joined nektar in january  as senior vice president and chief scientific officer to lead all aspects of discovery research at nektar dr doberstein brings over 7 years of experience in biotechnology research and development to the company prior to joining nektar dr doberstein was vice president of research at xoma where he was responsible for directing the discovery and development of their drug candidates including antibody discovery and support of clinical development through nonclinical safety translational medicine and pharmacokinetics pharmacodynamics prior to that dr doberstein served as vice president research at five prime therapeutics inc a protein and antibody discovery and development company where he built and led a high performance discovery research and process development group while at five prime he established programs resulting in multiple strategic alliances with pharmaceutical partners built a strong proprietary pipeline and moved multiple product candidates from concept to preind stages in diabetes oncology rheumatoid arthritis and osteoarthritis prior to that dr doberstein was vice president research at xencor an antibody and protein engineering and development company at xencor he was instrumental in advancing its protein platform technologies and preclinical product candidates before that he also held a number of senior positions at exelixis  companies in career na related markets  colleagues na related investments alias na industry rd in biotech environmental and various industries no marketing product yet tags drug discovery monoclonal antibodies biotechnologyassay development topics of influence na na careers achievements investments related people edit view all stephen k dobersteincareer  jan nektar therapeutics senior vice president and chief scientific officer oct to jan xoma ltd vice president of research may to oct five prime therapeutics vice president of research sep to apr xencor vice president of research competencies edit view all stephen k dobersteineducation  99 the johns hopkins university school of medicine biochemistry molecular and cell biology 9 university of delaware chemical engineering edit stephen k dobersteinachievements and recognitions add milestone no milestones has been recorded for stephen k doberstein edit stephen k dobersteinlinks add link no links has been recorded for stephen k doberstein stephen k dobersteininvestmentsacquisitions no investments has been recorded for stephen k doberstein stephen k dobersteininvestments representing others no investment reps has been recorded for stephen k doberstein stephen k dobersteinrelated people colleagues at nektar therapeutics howard w robin president and chief executive officer jan view all stephen k dobersteinrecommended market profiles  telemedicine  or more employees 9 companies social media marketing chiefmarteccom    employees  companies big data universe list of lists  or more employees  companies aggregated marketing technology  or more employees  companies shared economy landscape jeremiah owyang  or more employees 7 companies inside sales landscape  or more employees  companies stephen k doberstein  patents   free patent keyword monitoring and additional free benefits register now for free         browse inventors a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z     search freshpatents       online background check stephen k doberstein patentsrecent bibliographic sampling of stephen k doberstein patents listedpublished in the public domain by the uspto uspto patent application title   7  optimized fc variants and methods for their generationthe present invention relates to optimized fc variants methods for their generation and antibodies and fc fusions comprising optimized fc variants inventors gregory alan lazar arthur j chirino wei dang john desjarlais stephen k doberstein robert j hayes sher bahadur karki omid vafa xencor inc    optimized fc variants and methods for their generationthe present invention relates to optimized fc variants methods for their generation and antibodies and fc fusions comprising optimized fc variants inventors gregory alan lazar arthur j chirino wei dang john desjarlais stephen k doberstein robert j hayes sher bahadur karki omid vafa xencor inc  99  optimized fc variants and methods for their generationthe present invention relates to optimized fc variants methods for their generation and antibodies and fc fusions comprising optimized fc variants inventors gregory alan lazar arthur j chirino wei dang john desjarlais stephen k doberstein robert j hayes sher bahadur karki omid vafa xencor inc  9  compositions and methods of treating disease with fgfr fusion proteinsthe invention provides fgfr fusion proteins methods of making them and methods of using them to treat proliferative disorders including cancers and disorders of angiogenesis the fgfr fusion molecules can be made in cho cells and may comprise deletion mutations in the extracellular domains of the fgfrs which improve their inventors lewis t williams elizabeth bosch stephen k doberstein kevin hestir diane hollenbaugh ernestine lee minmin qin ali sadra justin wong ge wu hongbing zhang five prime therapeutics inc9    optimized fc variants and methods for their generationthe present invention relates to optimized fc variants methods for their generation and antibodies and fc fusions comprising optimized fc variants inventors gregory alan lazar arthur chirino wei dang john desjarlais stephen k doberstein robert j hayes sher bahadur karki omid vafa xencor inc    optimized fc variants and methods for their generationthe present invention relates to optimized fc variants methods for their generation and antibodies and fc fusions comprising optimized fc variants inventors gregory alan lazar arthur j chirino wei dang john r desjarlais stephen k doberstein robert j hayes sher bahadur karki omid vafa xencor inc  7  optimized fc variants and methods for their generationthe present invention relates to optimized fc variants methods for their generation and antibodies and fc fusions comprising optimized fc variants inventors gregory alan lazar arthur j chirino wei dang john desjarlais stephen k doberstein robert j hayes sher bahadur karki omid vafa xencor inc9    compositions and methods of use for mgdcsf in disease treatmentdisclosed is a newly identified secreted molecule identified herein as “monocyte granulocyte and dendritic cell colony stimulating factor” mgdcsf the polypeptide sequence and polynucleotides encoding the polypeptide sequence also provided is a procedure for producing the polypeptide by recombinant techniques employing for example vectors and host cells additionally procedures are inventors dirk behrens elizabeth bosch stephen k doberstein robert forgan halenbeck kevin hestir min mei huang ernestine lee haishan lin thomas linnemann shannon marshall justin wong ge wu aileen zhou cindy leo lewis t williams five prime therapeutics inc  99  compositions and methods of treating disease with fgfr fusion proteinsthe invention provides fgfr fusion proteins methods of making them and methods of using them to treat proliferative disorders including cancers and disorders of angiogenesis the fgfr fusion molecules can be made in cho cells and may comprise deletion mutations in the extracellular domains of the fgfrs which improve their inventors lewis t williams elizabeth bosch stephen k doberstein kevin hestir diane hollenbaugh ernestine lee minmin qin ali sadra justin wong ge wu hongbing zhang five prime therapeutics inc    compositions and methods of treating disease with fgfr fusion proteinsthe invention provides fgfr fusion proteins methods of making them and methods of using them to treat proliferative disorders including cancers and disorders of angiogenesis the fgfr fusion molecules can be made in cho cells and may comprise deletion mutations in the extracellular domains of the fgfrs which improve their inventors lewis t williams elizabeth bosch stephen k doberstein kevin hestir diane hollenbaugh ernestine lee minmin qin qin ali sadra justin wong ge wu hongbing zhang zhang five prime therapeutics inc99  7  optimized fc variants and methods for their generationthe present invention relates to optimized fc variants methods for their generation and antibodies and fc fusions comprising optimized fc variants inventors gregory alan lazar arthur j chirino wei dang john desjarlais stephen k doberstein robert j hayes sher bahadur karki omid vafa xencor inc    optimized fc variants and methods for their generationthe present invention relates to optimized fc variants methods for their generation and antibodies and fc fusions comprising optimized fc variants inventors gregory alan lazar arthur j chirino wei dang john desjarlais stephen k doberstein robert j hayes sher bahadur karki omid vafa xencor inc    optimized fc variants and methods for their generationthe present invention relates to optimized fc variants methods for their generation and antibodies and fc fusions comprising optimized fc variants inventors gregory alan lazar arthur j chirino wei dang john desjarlais stephen k doberstein robert j hayes sher bahadur karki omid vafa xencor inc    compositions and methods of use for mgdcsf in disease treatmentdisclosed is a newly identified secreted molecule identified herein as “monocyte granulocyte and dendritic cell colony stimulating factor” mgdcsf the polypeptide sequence and polynucleotides encoding the polypeptide sequence also provided is a procedure for producing the polypeptide by recombinant techniques employing for example vectors and host cells additionally procedures are inventors dirk behrens elizabeth bosch stephen k doberstein robert forgan halenbeck kevin hestir min mei huang ernestine lee haishan lin thomas linnemann shannon marshall justin g p wong ge wu aileen zhou cindy leo lewis t williams five prime therapeutics inc    compositions and methods of use for mgdcsf in disease treatmentdisclosed is a newly identified secreted molecule identified herein as “monocyte granulocyte and dendritic cell colony stimulating factor” mgdcsf the polypeptide sequence and polynucleotides encoding the polypeptide sequence also provided is a procedure for producing the polypeptide by recombinant techniques employing for example vectors and host cells additionally procedures are inventors dirk behrens elizabeth bosch stephen k doberstein robert forgan halenbeck kevin hestir min mei huang ernestine lee haishan lin thomas linnemann shannon marshall justin g p wong ge wu aileen zhou cindy leo lewis t williams five prime therapeutics inc99  9  human cdna clones comprising polynucleotides encoding polypeptides and methods of their usethe invention provides novel human fulllength cdna clones novel polynucleotides related polypeptides related nucleic acid and polypeptide compositions and related modulators such as antibodies and small molecule modulators the invention also provides methods to make and use these cdna clones polynucleotides polypeptides related compositions and modulators these methods include diagnostic inventors lewis t williams keting chu ernestine lee kevin hestir justin wong stephen k doberstein five prime therapeutics inc xencor inc five prime therapeutics inc five prime therapeutics incarchived may have duplicates  we are upgrading our archive   compositions and methods of use for mgdcsf in disease treatment the bibliographic references displayed about stephen k dobersteins patents are for a recent sample of stephen k dobersteins publicly published patent applications the inventorauthor may have additional bibliographic citations listed at the usptogov freshpatentscom is not associated or affiliated in any way with the authorinventor or the united states patenttrademark office but is providing this noncomprehensive sample listing for educational and research purposes using public bibliographic data published and disseminated from the united states patenttrademark office public datafeed this information is also available for free on the usptogov website if stephen k doberstein filed recent patent applications under another name spelling or location then those applications could be listed on an alternate page if no bibliographic references are listed here it is possible there are no recent filings or there is a technical issue with the listingin that case we recommend doing a search on the usptogov website sign up for the freshpatentscom free keyword monitor and check for keyword phrases ie rfid  wireless web development fuel cells etcyou will be notified when new patent applications and inventions are published that match your keywords also you can save for later research public patentinvention documents using our free organizer it takes only  seconds to sign up or loginadvertise on freshpatentscom  rates  infodesigncode   freshcontext llcfreshpatentscompatent data source patents published by the united states patent and trademark office usptoinformation published here is for researcheducational purposes only and in conjunction with our keyword monitor and is not meant to be used in place of the full uspto patent documentimages or a comprehensive patent archive search complete official applications are on file at the uspto and may contain additional dataimages freshpatentscom is not affiliated with or endorsed by the uspto or firmsindividuals or productsdesignsideas related to listed patents and there may be applicable trademarks or servicemarks within the documentsfreshpatentscom support  terms  conditions